Boehringer Ingelheim Advances Partnership with Brainomix to Improve Pulmonary Fibrosis Care

Boehringer Ingelheim’s strategic partnership with Brainomix is expanding to help improve care for patients with progressive pulmonary fibrosis (PPF).

This is a logical step for the partnership, as Brainomix specializes in AI-powered imaging tools for lung fibrosis and stroke. Meanwhile, Boehringer Ingelheim is recognized as a leader in providing therapeutic options for interstitial lung disease (ILD).

What Brainomix is Contributing

Now, Brainomix will leverage its e-Lung AI-driven imaging software platform. This technology, approved by the U.S. FDA, automatically detects and quantifies abnormalities on thoracic CT scans. This, in turn, helps clinicians identify even subtle changes more easily over time.

e-Lung has clinical validation in measuring lung features associated with ILDs. Patients with ILDs may see those diseases progress to PPF, which prompts irreversible lung damage and increased early mortality risk. Without treatment, lifespans may be as short as five years—yet diagnoses themselves can often take several years. Determining eligible patients for treatment, based on imaging, has to this point been challenging.

Results from a retrospective research study (REVISE-PPF) are being publicly presented on May 17. In brief, the study showed e-Lung could stratify patients at risk of PPF from a baseline CT scan. Additionally, it identified patients with radiologic evidence of PPF up to 28 months earlier than local clinical diagnoses.

Boehringer Ingelheim Seeks Clearer Diagnoses

“PPF can be challenging to diagnose,” said Emmanuelle Clerisme-Beaty, MD, Boehringer Ingelheim Senior Vice President, Medicine & Regulatory Affairs. “Innovations that enhance our ability to detect disease have the potential to improve patient outcomes.”

“The evidence generated to date for e-Lung is highly compelling,” said Brainomix CEO and Co-Founder Michalis Papadakis, PhD. “The technology has the potential to accelerate diagnosis by more than two years. This next phase will enable us to evaluate that potential at scale, providing robust real-world validation.”

A prospective mixed-methods study (PROGRESS-PPF) at multiple U.S. sites is the next phase of the Brainomix–Boehringer Ingelheim partnership.